Ocean Biomedical’s Anti-CHI3L1 patent coverage includes multiple methods of use for targeting a broad range of Cancers that include Lung...
SAN DIEGO, Oct. 01, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the...
Vancouver, British Columbia--(Newsfile Corp. - September 27, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or...
Naporafenib is a potential first-in-class and best-in-class pan-RAF inhibitor Erasca is also evaluating naporafenib plus trametinib in the ongoing SEACRAFT-2...
Continues customer expansion to hospital oncology departments for the outpatient treatment of non-melanoma skin cancersBOCA RATON, Fla., Sept. 25, 2024...
Phase 1/2 clinical study will evaluate the safety and preliminary efficacy of KSQ-004EX in advanced solid tumorsLEXINGTON, Mass., Sept. 24,...
The agreement has been signed upon successful conclusion of a clinical study in dogs with osteoarthritis RAMAT GAN, Israel, Sept....
-Trial to focus on particularly vulnerable subset of patients, following strong clinician interest in use of the Alpha DaRT in...
–Achilles to discontinue development of TIL-based cNeT therapy– –Cash position of $95.1 million as of June 30, 2024– –BofA Securities...
ROCHESTER, N.Y., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company...
Results from triple combination of efti, radiotherapy and KEYTRUDA® (pembrolizumab) to be presented at the Connective Tissue Oncology Society 2024...
MyRisk®, FirstGene®, Prequel®, and Foresight® studies among 10 datasets to be shared by MyriadSALT LAKE CITY, Sept. 18, 2024 (GLOBE...
Detailing the intricate process of early embryogenesis, this year's winning video provides insights into fundamental biological processes with far-reaching implications....
PHOENIX & FRIENDSWOOD, Texas--(BUSINESS WIRE)--$CSTL #COO--The Arizona Bioindustry Association, Inc. (AZBio) and Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving...
PHOENIX & FRIENDSWOOD, Texas--(BUSINESS WIRE)--$CSTL #COO--The Arizona Bioindustry Association, Inc. (AZBio) and Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving...
Investigational TAR-200 monotherapy demonstrates high complete response rate without the need for reinduction or additive therapy in patients who are...
Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer Brenetafusp is clinically...
-- Study Meets Overall Response Rate Primary Endpoint, Encouraging Secondary Endpoint Progression-Free Survival Data in Squamous Cell Carcinoma of the...
LUND, SWEDEN / ACCESSWIRE / September 14, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm:CANTA) today presented data from...
Bel-sar Demonstrated 80% Tumor Control Rate, 90% Visual Acuity Preservation, and a Highly Favorable Safety Profile Aura to Host a...